# Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:

> **NCT03875573** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Jules Bordet Institute** · enrollment: 147 (actual)

## Conditions studied

- Luminal B

## Interventions

- **DRUG:** Durvalumab
- **RADIATION:** Stereotactic Body Radiotherapy
- **DRUG:** Oleclumab

## Key facts

- **NCT ID:** NCT03875573
- **Lead sponsor:** Jules Bordet Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-11-06
- **Primary completion:** 2025-05-30
- **Final completion:** 2029-09-30
- **Target enrollment:** 147 (ACTUAL)
- **Last updated:** 2024-12-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03875573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03875573, "Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03875573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*